NASDAQ:ETNB 89bio - ETNB Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding 89bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $16.15 -0.79 (-4.66%) (As of 03/24/2023 12:27 PM ET) Add Compare Share Share Today's Range$15.75▼$18.0350-Day Range$10.50▼$16.9452-Week Range$2.00▼$18.03Volume5.85 million shsAverage Volume1.97 million shsMarket Capitalization$843.51 millionP/E RatioN/ADividend YieldN/APrice Target$25.38 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media 89bio MarketRank™ ForecastAnalyst RatingBuy3.13 Rating ScoreUpside/Downside89.8% Upside$33.25 Price TargetShort InterestBearish9.86% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 20 Articles This WeekInsider TradingSelling Shares$177,844 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.44) to ($2.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.00 out of 5 starsMedical Sector619th out of 989 stocksPharmaceutical Preparations Industry293rd out of 480 stocks 3.6 Analyst's Opinion Consensus Rating89bio has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.25, 89bio has a forecasted upside of 89.8% from its current price of $17.52.Amount of Analyst Coverage89bio has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.86% of the outstanding shares of 89bio have been sold short.Short Interest Ratio / Days to Cover89bio has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in 89bio has recently increased by 10.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yield89bio does not currently pay a dividend.Dividend Growth89bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ETNB. Previous Next 3.0 News and Social Media Coverage News Sentiment89bio has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for 89bio this week, compared to 2 articles on an average week.Search Interest76 people have searched for ETNB on MarketBeat in the last 30 days. This is an increase of 4% compared to the previous 30 days.MarketBeat Follows10 people have added 89bio to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 89bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $177,844.00 in company stock.Percentage Held by Insiders11.80% of the stock of 89bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.78% of the stock of 89bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for 89bio are expected to decrease in the coming year, from ($2.44) to ($2.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 89bio is -4.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 89bio is -4.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio89bio has a P/B Ratio of 5.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About 89bio (NASDAQ:ETNB) Stock89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.Read More Receive ETNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ETNB Stock News HeadlinesMarch 24, 2023 | finance.yahoo.com89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common StockMarch 24, 2023 | americanbankingnews.comRoyal Bank of Canada Increases 89bio (NASDAQ:ETNB) Price Target to $36.00March 24, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 24, 2023 | americanbankingnews.com89bio (NASDAQ:ETNB) PT Raised to $33.00March 24, 2023 | americanbankingnews.com89bio (NASDAQ:ETNB) PT Raised to $30.00 at HC WainwrightMarch 24, 2023 | americanbankingnews.com89bio (NASDAQ:ETNB) Given New $45.00 Price Target at Cantor FitzgeraldMarch 24, 2023 | americanbankingnews.comHC Wainwright Analysts Lift Earnings Estimates for 89bio, Inc. (NASDAQ:ETNB)March 22, 2023 | investorplace.comWhy Is 89bio (ETNB) Stock Up 34% Today?March 24, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 18, 2023 | americanbankingnews.comFY2023 Earnings Estimate for 89bio, Inc. (NASDAQ:ETNB) Issued By Cantor FitzgeraldMarch 18, 2023 | americanbankingnews.com89bio (NASDAQ:ETNB) Earns Outperform Rating from Royal Bank of CanadaMarch 16, 2023 | americanbankingnews.com89bio, Inc. (NASDAQ:ETNB) to Post Q1 2023 Earnings of ($0.54) Per Share, SVB Leerink ForecastsMarch 15, 2023 | finance.yahoo.comWall Street Analysts See an 80% Upside in 89BIO (ETNB): Can the Stock Really Move This High?March 15, 2023 | americanbankingnews.comSVB Leerink Comments on 89bio, Inc.'s Q2 2023 Earnings (NASDAQ:ETNB)March 10, 2023 | finance.yahoo.com89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateMarch 4, 2023 | finance.yahoo.com89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of CardiologyFebruary 21, 2023 | finance.yahoo.com89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of CardiologyJanuary 30, 2023 | 247wallst.comOrbimed Advisors Reduces Position in 89bioJanuary 22, 2023 | finance.yahoo.comWith stock up 19%, Insiders of 89bio, Inc. (NASDAQ:ETNB) must be wishing they had bought more last yearJanuary 4, 2023 | finance.yahoo.com89bio Provides Business Update and Outlook for 2023December 12, 2022 | finance.yahoo.com89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & HepatologyNovember 10, 2022 | finance.yahoo.com89bio Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 5, 2022 | finance.yahoo.com89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022October 18, 2022 | benzinga.comThinking about buying stock in RA Medical, Aveo Pharmaceuticals, FuboTV, Canoo, or 89bio? - AVEO Pharmace - BenzingaOctober 13, 2022 | finance.yahoo.com89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor ConferenceOctober 6, 2022 | seekingalpha.com89bio Still Has A Chance As NASH Race Heats Up (NASDAQ:ETNB) - Seeking AlphaSeptember 19, 2022 | nasdaq.comPre-market Movers: BCAN, REUN, FOXO, ETNB, INO… - NasdaqSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ETNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ETNB Company Calendar Last Earnings11/11/2021Today3/24/2023Next Earnings (Estimated)5/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ETNB CUSIPN/A CIK1785173 Webwww.89bio.com Phone415-432-9270FaxN/AEmployees41Year FoundedN/APrice Target and Rating Average Stock Price Forecast$33.25 High Stock Price Forecast$50.00 Low Stock Price Forecast$19.00 Forecasted Upside/Downside+49.8%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-83.74% Return on Assets-59.95% Debt Debt-to-Equity Ratio0.13 Current Ratio7.97 Quick Ratio7.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book5.65Miscellaneous Outstanding Shares52,230,000Free Float46,068,000Market Cap$884.78 million OptionableNot Optionable Beta0.73 Key ExecutivesMr. Rohan Palekar (Age 56)CEO & Director Comp: $829.41kMr. Quoc Le-Nguyen (Age 54)Chief Technical Operations Officer & Head of Quality Comp: $571.12kDr. Harry Mansbach M.D. (Age 57)Chief Medical Officer Comp: $603.22kMr. Ryan Stephen Martins (Age 44)Chief Financial Officer Mr. Shiva K. Natarajan (Age 56)Sr. VP of Fin. & Principal Accounting Officer Ms. Melissa AbelSr. VP of Commercial Strategy & CommunicationsMs. Amanda HillVP of People & CultureMs. Yun BaiVP & Head of CMCMr. Paul ShinSr. VP of R&D OperationsMore ExecutivesKey CompetitorsPOINT Biopharma GlobalNASDAQ:PNTANI PharmaceuticalsNASDAQ:ANIPPureTech HealthNASDAQ:PRTCIGM BiosciencesNASDAQ:IGMSCalliditas Therapeutics AB (publ)NASDAQ:CALTView All CompetitorsInsiders & InstitutionsRyan MartinsSold 2,540 sharesTotal: $35,280.60 ($13.89/share)Alliancebernstein L.P.Bought 130,877 shares on 2/16/2023Ownership: 0.259%Morgan StanleySold 27,254 shares on 2/15/2023Ownership: 0.208%Alps Advisors Inc.Bought 31,583 shares on 2/15/2023Ownership: 0.062%Man Group plcBought 17,804 shares on 2/15/2023Ownership: 0.035%View All Insider TransactionsView All Institutional Transactions ETNB Stock - Frequently Asked Questions Should I buy or sell 89bio stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last twelve months. There are currently 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ETNB shares. View ETNB analyst ratings or view top-rated stocks. What is 89bio's stock price forecast for 2023? 8 brokers have issued twelve-month target prices for 89bio's shares. Their ETNB share price forecasts range from $19.00 to $50.00. On average, they predict the company's stock price to reach $33.25 in the next twelve months. This suggests a possible upside of 96.3% from the stock's current price. View analysts price targets for ETNB or view top-rated stocks among Wall Street analysts. How have ETNB shares performed in 2023? 89bio's stock was trading at $12.73 at the beginning of the year. Since then, ETNB stock has increased by 33.1% and is now trading at $16.94. View the best growth stocks for 2023 here. Are investors shorting 89bio? 89bio saw a increase in short interest in February. As of February 28th, there was short interest totaling 5,150,000 shares, an increase of 10.8% from the February 13th total of 4,650,000 shares. Based on an average daily volume of 1,080,000 shares, the short-interest ratio is presently 4.8 days. View 89bio's Short Interest. When is 89bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. View our ETNB earnings forecast. How were 89bio's earnings last quarter? 89bio, Inc. (NASDAQ:ETNB) announced its quarterly earnings data on Thursday, November, 11th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by $0.35. What ETFs hold 89bio's stock? ETFs with the largest weight of 89bio (NASDAQ:ETNB) stock in their portfolio include AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Invesco Raymond James SB-1 Equity ETF (RYJ), Harbor Health Care ETF (MEDI), ALPS Medical Breakthroughs ETF (SBIO), Harbor Disruptive Innovation ETF (INNO), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB) and ProShares Ultra Nasdaq Biotechnology (BIB). What other stocks do shareholders of 89bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), Honeywell International (HON), Raytheon Technologies (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO). When did 89bio IPO? (ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager. What is 89bio's stock symbol? 89bio trades on the NASDAQ under the ticker symbol "ETNB." Who are 89bio's major shareholders? 89bio's stock is owned by a number of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (17.71%), Millennium Management LLC (3.08%), Marshall Wace LLP (2.94%), Point72 Asset Management L.P. (2.03%), Two Sigma Investments LP (1.41%) and Citigroup Inc. (1.07%). Insiders that own company stock include Gregory Grunberg, Longitude Capital Partners Iii, Ollin B Sykes, Orbimed Advisors Llc, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins. View institutional ownership trends. How do I buy shares of 89bio? Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is 89bio's stock price today? One share of ETNB stock can currently be purchased for approximately $16.94. How much money does 89bio make? 89bio (NASDAQ:ETNB) has a market capitalization of $884.78 million. The company earns $-102,030,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis. How can I contact 89bio? 89bio's mailing address is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. The official website for the company is www.89bio.com. The company can be reached via phone at 415-432-9270 or via email at investors@89bio.com. This page (NASDAQ:ETNB) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.